US 12,282,020 B2
Use of BMMFI Rep protein as biomarker for colorectal cancer
Timo Bund, Dossenheim (DE); Harald Zur Hausen, Wald-Michelbach (DE); Ethel-Michele De Villiers-Zur Hausen, Wald-Michelbach (DE); Claudia Tessmer, Schwarzach (DE); Mathias Heikenwalder, Heidelberg (DE); Achim Weber, Zurich (CH); and Amelie Burk-Körner, Heidelberg (DE)
Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, Heidelberg (DE)
Filed by DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, Heidelberg (DE)
Filed on Jul. 27, 2020, as Appl. No. 16/939,154.
Application 16/939,154 is a continuation in part of application No. PCT/EP2019/051868, filed on Jan. 25, 2019.
Claims priority of application No. 18154190 (EP), filed on Jan. 30, 2018.
Prior Publication US 2021/0003575 A1, Jan. 7, 2021
Int. Cl. G01N 33/574 (2006.01); G01N 33/577 (2006.01)
CPC G01N 33/57419 (2013.01) [G01N 33/577 (2013.01); G01N 2333/70503 (2013.01)] 4 Claims
 
1. A method for providing a diagnosis or predisposition for colorectal cancer (CRC) in a subject, comprising:
obtaining a sample from a subject;
detecting whether a Bovine Meat and Milk Factor Group 1 (BMMF1) Rep Protein is present in the sample by contacting the sample with one or more antibodies selected from the group consisting of Ab 1-5 (DSM ACC3327), Ab 5-2 (DSM ACC3328) and Ab 3-6 (DSM ACC3329) and detecting binding between BMMF1 and said one or more antibodies; and
providing a diagnosis or predisposition for CRC to the subject when the presence of BMMF1 in the sample is detected.